Ngm Biopharmaceuticals Inc [NGM] stock is trading at $1.62, up 4.52%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The NGM shares have gain 4.52% over the last week, with a monthly amount drifted -0.61%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 19, March 2024, NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting. In a post published today on Yahoo Finance, NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that two abstracts highlighting clinical data from the ongoing Phase 1/2 clinical trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, have been selected for presentation at the American Association for Cancer Research (AACR) Annual Meeting, being held April 5-10, 2024 in San Diego, CA.
From an analyst’s perspective:
Ngm Biopharmaceuticals Inc [NASDAQ: NGM] stock has seen the most recent analyst activity on March 12, 2024, when Raymond James downgraded its rating to a Mkt Perform. Previously, TD Cowen downgraded its rating to Market Perform on February 28, 2024. On February 27, 2024, downgrade downgraded it’s rating to Neutral. Citigroup started tracking the stock assigning a Buy rating and suggested a price target of $6 on May 03, 2023. Raymond James downgraded its rating to a Outperform and reduced its price target to $4 on October 18, 2022. Goldman downgraded its rating to Neutral for this stock on October 18, 2022, and downed its price target to $4. In a note dated October 17, 2022, Piper Sandler downgraded an Neutral rating on this stock.
Ngm Biopharmaceuticals Inc [NGM] stock has fluctuated between $0.60 and $4.69 over the past year. Currently, Wall Street analysts expect the stock to reach $16.5 within the next 12 months. Ngm Biopharmaceuticals Inc [NASDAQ: NGM] shares were valued at $1.62 at the most recent close of the market. An investor can expect a potential return of 918.52% based on the average NGM price forecast.
Analyzing the NGM fundamentals
Ngm Biopharmaceuticals Inc [NASDAQ:NGM] reported sales of 4.42M for the trailing twelve months, which represents a drop of -99.09%. Gross Profit Margin for this corporation currently stands at 0.26% with Operating Profit Margin at -34.29%, Pretax Profit Margin comes in at -32.23%, and Net Profit Margin reading is -31.66%. To continue investigating profitability, this company’s Return on Assets is posted at -0.83, Equity is -0.76 and Total Capital is -1.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.5567 points at the first support level, and at 1.4933 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.6567, and for the 2nd resistance point, it is at 1.6933.
Ngm Biopharmaceuticals Inc [NGM] reported earnings per share of -$0.33 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.39/share, meaning a difference of $0.06 and a surprise factor of 15.40%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.35 per share as compared to estimates of -$0.42 per share, a difference of $0.07 representing a surprise of 16.70%.
Ratios To Look Out For
For context, Ngm Biopharmaceuticals Inc’s Current Ratio is 7.79. As well, the Quick Ratio is 7.79, while the Cash Ratio is 2.93. Considering the valuation of this stock, the price to sales ratio is 30.59, the price to book ratio is 0.90.
Transactions by insiders
Recent insider trading involved COLUMN GROUP L P, Director, that happened on Nov 16 ’23 when 5840.0 shares were purchased. Director, COLUMN GROUP L P completed a deal on Nov 16 ’23 to buy 5840.0 shares. Meanwhile, Director COLUMN GROUP L P bought 5840.0 shares on Nov 16 ’23.
